flow trial semaglutide kidney outcomes nejm 2024 hazard ratio With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes flow trial semaglutide kidney outcomes

The best drug for you should be determined by your endocrinologist or primary healthcare provider, who can take into account individual considerations, such as your medical conditions and medical history, as well as any other medications you are taking

Outcomes : Response rates as reported in the literature range widely, from about 9% to 87%

Body composition substudies using dual-energy X-ray absorptiometry (DXA) have shown that while patients lost significant total weight, lean mass decreased proportionally less than fat mass

The study enrolled 338 participants with obesity across multiple dose groups, tracking outcomes over 48 weeks

Persson, E